Research Analysts’ Recent Ratings Updates for Novo Nordisk A/S (NVO)

Several analysts have recently updated their ratings and price targets for Novo Nordisk A/S (NYSE: NVO):

• 8/27/2026 – Novo Nordisk A/S was downgraded by Deutsche Bank Aktiengesellschaft from “hold” to “sell”.
• 8/12/2026 – Novo Nordisk A/S was given a new $47.00 price target by Berenberg Bank.
• 8/12/2026 – Novo Nordisk A/S was downgraded by Berenberg Bank from “buy” to “hold”.
• 8/11/2026 – Novo Nordisk A/S was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/6/2026 – Novo Nordisk A/S had its “market perform” rating reaffirmed by BMO Capital Markets. They now have a $47.00 price target on the stock.
• 8/5/2026 – Novo Nordisk A/S was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 7/20/2026 – Novo Nordisk A/S had its “sell (d+)” rating reaffirmed by Weiss Ratings.
• 7/20/2026 – Novo Nordisk A/S had its “neutral” rating reaffirmed by Citigroup Inc..
• 7/13/2026 – Novo Nordisk A/S was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/6/2026 – Novo Nordisk A/S had its “hold” rating reaffirmed by HSBC Holdings plc.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were paid a $0.5786 dividend. The ex-dividend date was Monday, August 17th. This represents a yield of 258.0%. Novo Nordisk A/S’s payout ratio is presently 20.05%.

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.